GlassScriptPhysician profile
Phillip Ralph Delio
NPI 1255358156
$131,793.82
in general payments reported to CMS, 2019-2025
25 companies · $8,220 in 2025
The $8,220 reported for 2025 was more than what 88% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,993 · 2020: $19K · 2021: $50K · 2022: $24K · 2023: $21K · 2024: $8,302 · 2025: $8,220.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $31K · Consulting Fee: $2,350 · Food and Beverage: $2,177 · Travel and Lodging: $1,652 · Education: $208.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $31,206.25 |
| Consulting Fee | $2,350.00 |
| Food and Beverage | $2,176.91 |
| Travel and Lodging | $1,651.91 |
| Education | $207.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $74,883.77 | 2021-2025 | Ubrelvy, Qulipta, Botox |
| Allergan, INC. | $18,710.16 | 2020-2021 | |
| Biohaven Pharmaceuticals, INC. | $18,662.62 | 2020-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $7,073.76 | 2022 | |
| W. L. Gore & Associates, INC. | $3,900.00 | 2020-2021 | |
| Biogen, INC. | $2,504.17 | 2019-2025 | Vumerity, Tysabri |
| Eli Lilly and Company | $2,200.00 | 2023 | |
| Amneal Pharmaceuticals LLC | $1,515.00 | 2021 | |
| Banner Life Sciences, LLC | $900.00 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $296.47 | 2020-2024 | |
| Genzyme Corporation | $240.00 | 2021 | |
| Eisai INC. | $225.99 | 2024-2025 | |
| Emd Serono, INC. | $191.51 | 2020-2024 | Mavenclad |
| Abbott Laboratories | $132.37 | 2024 | Infinity |
| Mdd US Operations, LLC | $119.01 | 2019 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $56.72 | 2020-2021 | |
| Argenx US, INC. | $31.56 | 2023 | Vyvgart |
| Acadia Pharmaceuticals INC | $30.78 | 2019 | |
| Pfizer INC. | $30.03 | 2023-2024 | |
| Medtronic USA, INC. | $28.93 | 2019 | |
| Ge Healthcare | $22.03 | 2025 | |
| Ceribell, INC. | $13.20 | 2023 | Ceribell Rapid Response Eeg |
| Novartis Pharmaceuticals Corporation | $13.00 | 2021 | |
| Ucb, INC. | $12.74 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Phillip Delio listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.